Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 117

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 117
---
 Materiel Development Activity (USAMMDA) for Arakoda supply chain upgrade support. Research revenue under this contract is recognized when we incur the direct costs eligible for reimbursement, up to the maximum allowable amount. Operating Expenses Research and Development Research and development costs for the periods presented primarily consist of contracted R&D services and costs associated with preparation for our Babesiosis trial in 2024 and, in 2023 related to our now halted COVID-19 clinical trial. We expense all research and development costs in the period in which they are incurred. Payments made prior to the receipt of goods or services to be used in research and development are recognized as prepaid assets and expensed over the service period as the services are provided. We have also issued shares of our common stock in exchange for research and development services. General and Administrative Expenses Our general and administrative expenses primarily consist of salaries, advertising and promotion expenses, professional services fees, such as consulting, audit, accounting and legal fees, general corporate costs and allocated costs, including facilities, information technology and amortization of intangibles. Interest and Other Income (Expense), Net Interest expense consists of interest accrued on our debt obligations and related amortization of debt discounts and deferred issuance costs. Other components of other income (expense), net include changes in the fair value of financial instruments, gains and losses on extinguishments of debt, and other miscellaneous income (expense). We also earn interest income from cash invested in interest-bearing accounts as well as cash equivalents and short-term investments consisting of certificates of deposits with original maturities ranging from three to six months. 66 Results of Operations The following table sets forth our results of operations for the periods presented:

| Consolidated Statements of Operations Data:                        |     | 2024 |            For the 
 Three Months Ended 
      September 30, |   |     | 2023 |            |   |     | 2024 |           For the 
 Nine Months Ended 
     September 30, |   |     | 2023 |            |   |
|:-------------------------------------------------------------------|:----|:-----|-------------------:|:--|:----|:-----|-----------:|:--|:----|:-----|------------------:|:--|:----|:-----|-----------:|:--|
| Product Revenues - net of Discounts and Rebates                    |     | $    |            135,293 |   |     | $    |     51,188 |   |     | $    |